Title :

Randomized, double-blind trial of f14512, a polyamine-vectorized anticancer drug, compared with etoposide phosphate, in dogs with naturally occurring lymphoma

Author(s) :

Boye, Pierre [Auteur]
Floch, Franck [Auteur]
Serres, Francois [Auteur]
Segaoula, Zacharie [Auteur]
Hordeaux, Juliette [Auteur]
Pascal, Quentin [Auteur]
Coste, Virginie [Auteur]
Courapied, Sandy [Auteur]
Bouchaert, Emmanuel [Auteur]
Rybicka, Agata [Auteur]
Mazuy, Claire [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 [PRISM]
Marescaux, Laurent [Auteur]
Geeraert, Kevyn [Auteur]
Fournel-Fleury, Corinne [Auteur]
Duhamel, Alain [Auteur]
Machuron, Francois [Auteur]
Ferre, Pierre [Auteur]
Petain, Aurelie [Auteur]
Guilbaud, Nicolas [Auteur]
Tierny, Dominique [Auteur]
Gomes, Bruno [Auteur]

Journal title :

Oncotarget

Abbreviated title :

Oncotarget

Volume number :

11

Pages :

671-686

Publication date :

2020-02-18

ISSN :

1949-2553

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Purpose: F14512 is an epipodophyllotoxin derivative from etoposide, combined with a spermine moiety introduced as a cell delivery vector. The objective of this study was to compare the safety and antitumor activity of ...
Show more >Purpose: F14512 is an epipodophyllotoxin derivative from etoposide, combined with a spermine moiety introduced as a cell delivery vector. The objective of this study was to compare the safety and antitumor activity of F14512 and etoposide phosphate in dogs with spontaneous non-Hodgkin lymphoma (NHL) and to investigate the potential benefit of F14512 in P-glycoprotein (Pgp) overexpressing lymphomas. Experimental Design: Forty-eight client-owned dogs with intermediate to high-grade NHL were enrolled into a randomized, double-blind trial of F14512 versus etoposide phosphate. Endpoints included safety and therapeutic efficacy. Results: Twenty-five dogs were randomized to receive F14512 and 23 dogs to receive etoposide phosphate. All adverse events (AEs) were reversible, and no treatment-related death was reported. Hematologic AEs were more severe with F14512 and gastrointestinal AEs were more frequent with etoposide phosphate. F14512 exhibited similar response rate and progression-free survival (PFS) as etoposide phosphate in the global treated population. Subgroup analysis of dogs with Pgp-overexpressing NHL showed a significant improvement in PFS in dogs treated with F14512 compared with etoposide phosphate. Conclusion: F14512 showed strong therapeutic efficacy against spontaneous NHL and exhibited a clinical benefice in Pgp-overexpressing lymphoma superior to etoposide phosphate. The results clearly justify the evaluation of F14512 in human clinical trials.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
INSERM
Université de Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
• Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192

Submission date :

2022-06-15T13:57:28Z